350 related articles for article (PubMed ID: 15127320)
21. Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: association with increased plasminogen activator inhibitor-1.
Aso Y; Matsumoto S; Fujiwara Y; Tayama K; Inukai T; Takemura Y
Metabolism; 2002 Apr; 51(4):471-6. PubMed ID: 11912556
[TBL] [Abstract][Full Text] [Related]
22. Effect of ACE inhibition on the fibrinolytic system in patients requiring coronary artery bypass grafting.
Walter T; Szabo S; Kazmaier S; Suselbeck T; Borggrefe M; Hoffmeister HM
Thorac Cardiovasc Surg; 2009 Sep; 57(6):368-71. PubMed ID: 19707983
[TBL] [Abstract][Full Text] [Related]
23. Tight glycemic control may favor fibrinolysis in patients with sepsis.
Savioli M; Cugno M; Polli F; Taccone P; Bellani G; Spanu P; Pesenti A; Iapichino G; Gattinoni L
Crit Care Med; 2009 Feb; 37(2):424-31. PubMed ID: 19114908
[TBL] [Abstract][Full Text] [Related]
24. A randomised, controlled study of the effects of aerobic exercise and dietary fish on coagulation and fibrinolytic factors in type 2 diabetics.
Dunstan DW; Mori TA; Puddey IB; Beilin LJ; Burke V; Morton AR; Stanton KG
Thromb Haemost; 1999 Mar; 81(3):367-72. PubMed ID: 10102462
[TBL] [Abstract][Full Text] [Related]
25. Estrogen treatment improves arterial distensibility, fibrinolysis, and metabolic profile in postmenopausal women with type 2 diabetes mellitus.
Sztejnsznajd C; Silva ME; Nussbacher A; Gebara OE; D'Amico EA; Rocha DM; da Rocha TR; Santos RF; Wajngarten M; Fukui RT; Correia MR; Wajchenberg BL; Ursich MJ
Metabolism; 2006 Jul; 55(7):953-9. PubMed ID: 16784970
[TBL] [Abstract][Full Text] [Related]
26. Effect of fluvastatin and valsartan, alone and in combination, on postprandial vascular inflammation and fibrinolytic activity in patients with essential hypertension.
Liu L; Zhao SP; Zhou HN; Li QZ; Li JX
J Cardiovasc Pharmacol; 2007 Jul; 50(1):50-5. PubMed ID: 17666915
[TBL] [Abstract][Full Text] [Related]
27. [Activation of fibrynolysis in children with chronic B or C hepatitis].
Michalska K; Szaflarska-Popławska A; Dymek G; Kotschy M
Pol Merkur Lekarski; 2004 Oct; 17(100):316-20. PubMed ID: 15690691
[TBL] [Abstract][Full Text] [Related]
28. Fibrinolysis system in patients with bronchial asthma.
Banach-Wawrzeńczyk E; Dziedziczko A; Rość D
Med Sci Monit; 2000; 6(1):103-7. PubMed ID: 11208294
[TBL] [Abstract][Full Text] [Related]
29. Decreased levels of PAI-1 and alpha 2-antiplasmin contribute to enhanced fibrinolytic activity in divers.
Radziwon P; Olszański R; Tomaszewski R; Lipska A; Dabrowiecki Z; Korzeniewski K; Siermontowski P; Boczkowska-Radziwon B
Thromb Res; 2007; 121(2):235-40. PubMed ID: 17521709
[TBL] [Abstract][Full Text] [Related]
30. Early inhibition of activated fibrinolysis predicts microbial infection, shock and mortality in febrile medical patients.
Raaphorst J; Johan Groeneveld AB; Bossink AW; Erik Hack C
Thromb Haemost; 2001 Aug; 86(2):543-9. PubMed ID: 11522001
[TBL] [Abstract][Full Text] [Related]
31. Fibrinolytic dysfunction in insulin-resistant women with previous gestational diabetes.
Farhan S; Winzer C; Tura A; Quehenberger P; Bieglmaier C; Wagner OF; Huber K; Waldhäusl W; Pacini G; Kautzky-Willer A
Eur J Clin Invest; 2006 May; 36(5):345-52. PubMed ID: 16634839
[TBL] [Abstract][Full Text] [Related]
32. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.
Kruszynska YT; Yu JG; Olefsky JM; Sobel BE
Diabetes; 2000 Apr; 49(4):633-9. PubMed ID: 10871202
[TBL] [Abstract][Full Text] [Related]
33. Levels of fibrinolytic activators and inhibitors in plasma after severe trauma.
Sørensen JV
Blood Coagul Fibrinolysis; 1994 Feb; 5(1):43-9. PubMed ID: 7514044
[TBL] [Abstract][Full Text] [Related]
34. Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.
Triplitt C; Glass L; Miyazaki Y; Wajcberg E; Gastaldelli A; De Filippis E; Cersosimo E; DeFronzo RA
Diabetes Care; 2006 Nov; 29(11):2371-7. PubMed ID: 17065670
[TBL] [Abstract][Full Text] [Related]
35. A strong inverse relationship between PAI-1 and Lp(a) in hypertensive Type 2 diabetic patients.
Testa R; Bonfigli AR; Sirolla C; Pieri C; Marra M; Antonicelli R; Manfrini S; Compagnucci P; Testa I
Diabetes Nutr Metab; 1999 Dec; 12(6):400-6. PubMed ID: 10782561
[TBL] [Abstract][Full Text] [Related]
36. Vitamin E intake reduces plasminogen activator inhibitor type 1 in T2DM patients.
Bonfigli AR; Pieri C; Manfrini S; Testa I; Sirolla C; Ricciotti R; Marra M; Compagnucci P; Testa R
Diabetes Nutr Metab; 2001 Apr; 14(2):71-7. PubMed ID: 11383676
[TBL] [Abstract][Full Text] [Related]
37. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients--relationship with plasma insulin.
Juhan-Vague I; Roul C; Alessi MC; Ardissone JP; Heim M; Vague P
Thromb Haemost; 1989 Jun; 61(3):370-3. PubMed ID: 2678583
[TBL] [Abstract][Full Text] [Related]
38. A study on the action of vitamin E supplementation on plasminogen activator inhibitor type 1 and platelet nitric oxide production in type 2 diabetic patients.
Vignini A; Nanetti L; Moroni C; Testa R; Sirolla C; Marra M; Manfrini S; Fumelli D; Marcheselli F; Mazzanti L; Rabini RA
Nutr Metab Cardiovasc Dis; 2008 Jan; 18(1):15-22. PubMed ID: 17949955
[TBL] [Abstract][Full Text] [Related]
39. Plasminogen activator inhibitor-1 and tissue-plasminogen activator in minority adolescents with type 2 diabetes and obesity.
Umpaichitra V; Hussain MM; Castells S
Pediatr Res; 2005 Sep; 58(3):483-7. PubMed ID: 15901895
[TBL] [Abstract][Full Text] [Related]
40. Dyslipidemias and fibrinolysis.
Puccetti L; Bruni F; Pasqui AL; Pastorelli M; Bova G; Cercignani M; Palazzuoli A; Auteri A
Ital Heart J; 2002 Oct; 3(10):579-86. PubMed ID: 12478815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
